We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ARAB HEALTH - INFORMA

Download Mobile App




Events

09 Feb 2026 - 12 Feb 2026
22 Feb 2026 - 24 Feb 2026

Novel Ophthalmic Device Screens AMD Susceptibility

By HospiMedica International staff writers
Posted on 05 Jul 2017
An innovative device rapidly assesses macular pigment density, a marker for increased risk of age-related macular degeneration (AMD), the worldwide leading cause of incurable blindness in people over 55.

Developed at the University of Bristol (United Kingdom), the device is based on an entoptic phenomenon that allows certain people to perceive polarization of light as a yellow horizontal bar or bow-tie shape visible in the center of the visual field, typically occupying roughly 3–5 degrees of vision. More...
The direction of light polarization is perpendicular to the yellow bar; fainter bluish or purplish areas may be visible. Dr. Shelby Temple, PhD, of the School of Biological Sciences first encountered the phenomenon while studying the ability of octopuses, cuttlefish, and coral reef fish to see polarized light.

“What I was seeing was an effect known as Haidinger’s brushes, which is an effect that happens within the eye when people perceive polarized light. A person’s ability to see this phenomenon is linked to an aspect of eye health and can be an early indicator of disease,” explained Dr. Temple. “It became clear that the tools I had developed for fish could become the foundation for a novel ophthalmic device that could rapidly screen people for susceptibility to AMD.”

“If we can catch this early, people can make simple changes, like eating more brightly colored fruits and vegetables, quitting smoking and wearing protective eyewear, to help reduce the chances of going blind later in life,” added Dr. Temple, who is a co-founder of Azul Optics, a company created to commercialize the technology. Dr. Shelby Temple recently received the UK Biotechnology and Biological Sciences Research Council award of Innovator of the Year 2017 for his research.

“The BBSRC Innovator of the Year competition recognizes and rewards BBSRC-funded scientists that have identified and taken an active part in realizing the impact from their research,” said Karen Lewis, interim executive director at the BBSRC. “Dr. Temple’s technology has the potential to make a significant difference to people’s lives. The journey that Dr. Temple is taking to realize this opportunity from very fundamental research epitomizes the spirit of the competition. As well as being named Innovator of the Year 2017, Dr. Temple also received the award in the Commercial Impact category.”

AMD is a major cause of blindness and visual impairment in older adults in the center of the visual field (the macula) due to damage to the retina. Occurring in both dry and wet forms, AMD makes it difficult or impossible to read or recognize faces, although enough peripheral vision remains to allow other activities of daily life. In the dry (nonexudative) form, cellular debris called drusen accumulates between the retina and the choroid, and the retina can become detached. In the more severe wet (exudative) form, blood vessels grow from the choroid behind the retina, and the retina can also become detached.

Related Links:
University of Bristol


Gold Member
Real-Time Diagnostics Onscreen Viewer
GEMweb Live
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Endoscopy Display
E190
IV Therapy Cart
Avalo I.V Therapy Cart
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Surgical Techniques

view channel
Image: The light-activated Janus patches also hold great potential for various applications beyond neurosurgery (Kang, et al. Chemical Engineering Journal, 2026; DOI: 10.1016/j.cej.2025.171881)

Light-Activated Tissue Adhesive Patch Achieves Rapid and Watertight Neurosurgical Sealing

Durotomy, a tear in the dura mater during neurosurgery, can lead to cerebrospinal fluid leakage, delayed healing, headaches, and serious infections. Achieving a reliable, watertight dural closure is therefore... Read more

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: WHX in Dubai brings together over 235,000 professional visits and more than 4,300 global exhibitors from more than 180 countries

WHX in Dubai (formerly Arab Health) to bring together key UAE government entities during the groundbreaking 2026 edition

World Health Expo (WHX), formerly Arab Health, will bring together the UAE’s health authorities and leading healthcare sector bodies when the exhibition debuts at the Dubai Exhibition Centre (DEC) from... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.